Baseline demographic and clinical characteristics (all treated patients)
| Characteristic . | Patients (N = 92) . |
|---|---|
| Age, median (range), y | 67 (37-87) |
| Male sex | 48 (52) |
| Disease stage at diagnosis* | |
| I | 8 (9) |
| II | 12 (13) |
| III | 30 (33) |
| IV | 41 (45) |
| Bone marrow involvement | |
| Yes | 29 (32) |
| No | 55 (60) |
| Not reported | 8 (9) |
| FLIPI score at diagnosis | |
| 0-1 | 8 (9) |
| 2 | 20 (22) |
| 3-5 | 38 (41) |
| Not reported | 26 (28) |
| Number of prior lines of therapy | |
| Median (range) | 3 (2-10) |
| 2 | 34 (37) |
| 3 | 19 (21) |
| ≥4 | 39 (42) |
| Disease status at baseline | |
| Relapsed | 60 (65) |
| Refractory | 32 (35) |
| Progression from diagnosis to progression after first-line therapy | |
| Median (95% CI), y | 2.4 (1.7-3.1) |
| <2 y | 41 (45) |
| ≥2 y | 50 (55) |
| Prior radiotherapy | 29 (32) |
| Prior autologous HCT | 15 (16) |
| Characteristic . | Patients (N = 92) . |
|---|---|
| Age, median (range), y | 67 (37-87) |
| Male sex | 48 (52) |
| Disease stage at diagnosis* | |
| I | 8 (9) |
| II | 12 (13) |
| III | 30 (33) |
| IV | 41 (45) |
| Bone marrow involvement | |
| Yes | 29 (32) |
| No | 55 (60) |
| Not reported | 8 (9) |
| FLIPI score at diagnosis | |
| 0-1 | 8 (9) |
| 2 | 20 (22) |
| 3-5 | 38 (41) |
| Not reported | 26 (28) |
| Number of prior lines of therapy | |
| Median (range) | 3 (2-10) |
| 2 | 34 (37) |
| 3 | 19 (21) |
| ≥4 | 39 (42) |
| Disease status at baseline | |
| Relapsed | 60 (65) |
| Refractory | 32 (35) |
| Progression from diagnosis to progression after first-line therapy | |
| Median (95% CI), y | 2.4 (1.7-3.1) |
| <2 y | 41 (45) |
| ≥2 y | 50 (55) |
| Prior radiotherapy | 29 (32) |
| Prior autologous HCT | 15 (16) |
Data are reported as n (%), unless noted otherwise.
FLIPI, Follicular Lymphoma International Prognostic Index.
Disease stage at diagnosis was not reported for 1 patient.